Sugi Predict

Sugi Predict / Compounds / SCHEMBL1626660

SCHEMBL1626660

SCHEMBL1626660

CCOC(=O)C1=C(O)c2cc(Cl)ccc2C2(CCC3(CC2)OCC(C)(C)CO3)C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SPR P35270 1/20 0.62
▸ GAA P10253 2/20 0.37
▸ KDM4E B2RXH2 5/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MAPK1 P28482 2/20 0.34
▸ MAOB P27338 1/20 0.34
▸ HPGD P15428 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ ALOX15 P16050 3/20 0.34
▸ MAPT P10636 3/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ LMNA P02545 2/20 0.34
▸ TNF P01375 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ ALOX12 P18054 1/20 0.34
▸ CCR6 P51684 1/20 0.34
▸ RUNX1 Q01196 1/20 0.34
▸ CBFB Q13951 1/20 0.34
▸ HKDC1 Q2TB90 1/20 0.34
▸ NOD2 Q9HC29 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626619 0.85 SPR (0.72) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1626308 0.85 SPR (0.72) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1627845 0.84 SPR (0.68) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1626669 0.84 SPR (0.71) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1627090 0.82 SPR (0.64) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1627480 0.81 SPR (0.61) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1626623 0.80 SPR (0.42) SPRMAPT
SCHEMBL1626468 0.78 SPR (0.59) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1626821 0.77 SPR (0.57) SPRGAAKDM4EKMT2AMAPK1
SCHEMBL1626493 0.76 SPR (0.57) SPRGAAKDM4EKMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928139-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2011-04-19 — — US disclosed
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF AMGEN INC. (US) 2010-02-25 — — US disclosed
US-7635715-B2 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-12-22 — — US disclosed
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof AMGEN INC. (US) 2009-04-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048572-A1 NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF EGLN2, EGLN3, HIF1AN SPR 754/4885GAA 347/4885KDM4E 977/4885
US-20090093483-A1 Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof EGLN2, EGLN3, HIF1AN SPR 754/4885GAA 347/4885KDM4E 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.